Tissue-specific enhancer-gene maps from multimodal single-cell data identify causal disease alleles

Saori Sakaue[1,2,3], Kathryn Weinand[1,2,3,4], Kushal K. Dey[3,5], Karthik Jagadeesh[3,5], Masahiro Kanai[3,6,7,8], Gerald F. M. Watts[9], Zhu Zhu[9], Accelerating Medicines Partnership® RA/SLE Program and Network, Michael B. Brenner[9], Andrew McDavid[10], Laura T. Donlin[11,12], Kevin Wei[9], Alkes L. Price[3,5,13], Soumya Raychaudhuri[1,2,3,4,14,*]

1. Center for Data Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2. Divisions of Genetics and Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
3. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
4. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
6. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
7. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
8. Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, USA
9. Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
10. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA
11. Hospital for Special Surgery, New York, NY, USA
12. Weill Cornell Medicine, New York, NY, USA
13. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA
14. Centre for Genetics and Genomics Versus Arthritis, University of Manchester, Manchester, UK

*Address correspondence to:
Soumya Raychaudhuri
77 Avenue Louis Pasteur, Harvard New Research Building, Suite 250D
Boston, MA 02446, USA.
soumya@broadinstitute.org
617-525-4484 (tel); 617-525-4488 (fax)

Sakaue et al

Abstract

Translating genome-wide association study (GWAS) loci into causal variants and genes requires accurate cell-type-specific enhancer-gene maps from disease-relevant tissues. Building enhancer-gene maps is essential but challenging with current experimental methods in primary human tissues. We developed a new non-parametric statistical method, SCENT (Single-Cell ENhancer Target gene mapping) which models association between enhancer chromatin accessibility and gene expression in single-cell multimodal RNA-seq and ATAC-seq data. We applied SCENT to 9 multimodal datasets including > 120,000 single cells and created 23 cell-type-specific enhancer-gene maps. These maps were highly enriched for causal variants in eQTLs and GWAS for 1,143 diseases and traits. We identified likely causal genes for both common and rare diseases. In addition, we were able to link somatic mutation hotspots to target genes. We demonstrate that application of SCENT to multimodal data from disease-relevant human tissue enables the scalable construction of accurate cell-type-specific enhancer-gene maps, essential for defining variant function.

Main

Introduction

Genome-wide association studies (GWAS) have comprehensively mapped loci for human

diseases[1–4]. These loci harbor untapped insights about causal mechanisms that can point to

novel therapeutics[2,5]. However, only rarely are we able to define causal variants or their target

genes. Of the hundreds of associated variants that may be present in a single locus, only one or

a few may be causal; others are associated since they tag causal variants[2,6,7]. Moreover, causal

genes may also be challenging to determine, since causal variants lie in non-coding regions in

90% of the time[8–10], may regulate distant genes[11–13], and may employ context-specific

regulatory mechanisms[14–17].

To define causal variants and genes, previous studies have used both statistical and

experimental approaches. Statistical fine-mapping[18–23] can narrow the set of candidate causal

variants, and is more effective when genetic studies include diverse ancestral backgrounds with

different allele frequencies and linkage disequilibrium structures (LD)[24–28]. However, these

approaches alone are seldom able to identify true causal variants with confidence[7,23,29–32]. To

define causal genes, previous studies have built enhancer-gene maps, that can be used to

prioritize causal variants in enhancers and link causal variants to genes they regulate. These

maps often require large-scale epigenetic and transcriptomic atlases (e.g., Roadmap[33],

BLUEPRINT[34], and ENCODE[35]). By using these atlases, enhancer-gene maps have been built

by correlating epigenetic activity (i.e., enhancer activity; e.g., histone mark ChIP-seq and bulk

ATAC-seq) with gene expression (e.g., RNA-seq)[36,37], by combining epigenetic activity and

probability of physical contact with the gene[38,39], or by integrating multiple linking strategies to

create composite scores [40]. However, current methods largely use bulk tissues or cell lines.

Bulk data potentially (i) cannot be easily applied to rare cell populations (ii) obscures the

cell-type-specific nature of gene regulation and (iii) requires hundreds of experimentally

characterized samples, necessitating consortium-level efforts. While perturbation experiments

(e.g., CRISPR interference[41] or base editing[42]) can point to causal links between enhancers

and genes, they are difficult to scale because they require the development of cell- or

tissue-type specific experimental protocols [43].

Advances in single-cell technologies offer new opportunities for building cell-type specific

enhancer-gene maps. Multimodal protocols now enable joint capture of epigenetic activity by

ATAC-seq alongside early transcriptional activity with nuclear RNA-seq[44–48] . These methods

are easily applied at scale to cells in human primary tissues without disaggregation, making it

possible to easily query many samples from disease-relevant tissues. Gene-enhancer maps

can be built from this data if links between open chromatin and genes can be accurately

established. Since each observation is at a cell-level resolution, statistical power should exceed

bulk-tissue-based methods. However, the sparse and non-parametric nature of RNA-seq and

ATAC-seq in single-cell experiments makes confident identification of these links challenging.

To date, most methods use linear regression models to link enhancers and genes (e.g.,

ArchR[49] and Signac [50]) despite these sparse and non-parametric features or only utilize

co-accessibility of regulatory regions from ATAC-seq but not gene expression data from

sc-RNA-seq (e.g., Cicero[51]).   These previous methods have not widely demonstrated efficacy

in practice for fine-mapping of causal variants and genes in complex traits.

In this context, we developed Single-Cell Enhancer Target gene mapping (SCENT), to

accurately map enhancer-gene pairs where an enhancer's activity (i.e. peak accessibility) is

associated with gene expression across individual single cells. We use Poisson regression and

non-parametric bootstrapping[52] to account for the sparsity and non-parametric distributions. We

predicted that peaks with gene associations identified by SCENT are more likely to be

functionally important. We apply SCENT to 9 multimodal datasets to build 23 cell-type specific

enhancer-gene maps. We show that SCENT enhancers are highly enriched in statistically

fine-mapped putative causal variants for eQTL and GWAS. We use SCENT enhancer-gene

map to define causal variants, genes, and cell types in common and rare disease loci and

somatic mutation hotspots, which has not been previously demonstrated by conventional

enhancer-gene mapping based on bulk-tissues.

Results

Overview of SCENT

To identify (1) active *cis*-regulatory regions and (2) their target genes (3) in a given cell type, we

leveraged single-cell multimodal datasets. SCENT accurately identifies significant association

between chromatin accessibility of regulatory regions (i.e., peaks) from ATAC-seq and gene

expression from RNA-seq across individual single cells (**Figure 1a**). Those associations can be

used for prioritizing (1) putative causal variants if they are in regulatory regions that are

associated with expression of a gene, (2) putative causal genes if they are associated with the

identified regulatory region and (3) the critical cell types based on which map the relevant

association is identified in. We assessed whether binarized chromatin accessibility in each of

the ATAC peaks is associated with expression counts for each gene in *cis* (<500kb from gene

body), testing one peak-gene pair at a time in each cell type (see **Methods**). We tested each

cell type separately to capture cell-type-specific gene regulation and to avoid spurious

peak-gene associations due to gene co-regulation across cell types.

Since both RNA-seq and ATAC-seq data are generally sparse[50,53–56], we used Poisson

regression to model the effect of chromatin accessibility on gene expression accounting for

donor effects and cell-level factors capturing data quality, such as pesssrcentage of

mitochondrial reads. However, gene expression counts are highly variable across genes

(**Figure 1b**; **Supplementary Figure 1a**). Genes that are highly expressed and dispersed might

inflate association test statistics. This inflation was even apparent in data where we permuted

cell barcodes to disrupt any underlying association between ATAC and RNA profiles

(**Supplementary Figure 1b**). Common analytical statistical models (e.g., linear, negative

binomial and Poisson regression) all demonstrated inflated statistics (**Supplementary Figure**

1c-e). Therefore, to accurately estimate the error and significance of the effect of each

peak-gene pair, we implemented bootstrapping framework (i.e., resampling cells with

replacement; see **Methods**). This resulted in well-calibrated statistics with appropriate type I

error (**Supplementary Figure 1f**). For each accessible chromatin peak and gene expression in

each cell type, SCENT estimates an effect size, reflecting the strength of the regulatory effect,

and sign, reflecting enhancing versus silencing effects.

Figure 1. Schematic overview of SCENT and SCENT enhancer-gene pairs across 9 single-cell multimodal datasets. a. SCENT identifies (1) active *cis*-regulatory regions and (2) their target genes in (3) a specific cell type. Those SCENT results can be used to define causal variants, genes, and cell types for GWAS loci. **b**. SCENT models association between chromatin accessibility from ATAC-seq and gene expression from RNA-seq across individual cells in a given cell type. **c**. 9 single-cell datasets on which we applied SCENT to create 23 cell-type-specific enhancer-gene map. The cells in each dataset are described in UMAP embeddings from RNA-seq and colored by cell types.

Discovery of cell-type-specific SCENT enhancer-gene links

We obtained a total of nine single-cell multimodal datasets from diverse human tissues

representing 13 cell-types (immune-related, hematopoietic, neuronal, and pituitary). Since we

are interested in rheumatoid arthritis and other autoimmune diseases, we created a

disease-relevant inflammatory tissue dataset by obtaining inflamed synovial tissues from ten

rheumatoid arthritis (RA) and two osteoarthritis (OA) patients (arthritis-tissue dataset; n_{donor} =

12). Applying stringent QC to these multimodal data, we obtained information on 30,893 cells

(see **Methods**). In addition, we obtained eight public data sets with 129,672 cells. In total we

had data from 160,565 cells [46,57–61]. We analyzed 16,621 genes and 1,193,842 open chromatin

peaks in *cis* after QC (4,753,521 peak-gene pairs; **Figure 1c**, **Supplementary Table 1**). After

clustering cells and annotating them with cell labels, we applied SCENT individually to each of

the cell types with n_{cells} > 500 within each dataset to construct 23 enhancer-gene maps. SCENT

identified 87,648 cell-type-specific peak-gene links (false discovery rate (FDR) < 10%, **Figure**

2a, **Supplementary Figure 2**). Each gene had variable number of associated peaks in *cis*

(from 0 to 97, mean = 4.13, **Supplementary Figure 3a**).

To assess replicability of SCENT peak-gene links across datasets, we used

arthritis-tissue dataset, which had the largest number of significant peak-gene pairs as a

stringent discovery dataset. We compared the effects from the arthritis-tissue dataset in the

same cell-type with those from other datasets (B cell, T/NK cell and myeloid cell;

Supplementary Table 2a; see **Methods**). Despite different tissue contexts, we confirmed high

directional concordance of the effect of chromatin accessibility on gene expression for

peak-gene pairs significant in both datasets (mean Pearson $r = 0.62$ of effect sizes, 99% mean

concordance across all the datasets: **Supplementary Figure 3b**). For comparison, we tested

two popular linear parametric single-cell multimodal methods, ArchR[56] or Signac[50]. When

comparing with the same discovery and replication data (i.e., arthritis-tissue dataset as a

discovery and public PBMC as a replication), we noted lower directional concordance and effect

correlation in these previous methods than in SCENT (*55*)(mean Pearson's $r = 0.31$, 62% mean

directional concordance in ArchR and $r = 0.24$, 98% mean directional concordance in Signac;

Supplementary Table 2b and **c**). These results argue that SCENT can more reproducibly

detect enhancer-gene links compared with previous parametric methods for single-cell

multimodal data.

Figure 2. SCENT identified functionally active and evolutionary conserved *cis*-regulatory regions from single-cell multimodal data.

a. The number of significant gene-peak pairs discovered by SCENT with FDR < 10%. Each dot represents the number of significant gene-peak pairs in a given cell type in a dataset (y-axis) as a function of the number of cells in each cell type in a dataset (x-axis), colored by the dataset. **b**. The effect size (beta) of chromatin accessibility on the gene expression from Poisson regression (y-axis). Each dot is a significant gene-peak pair and plotted against the distance between the peak and the transcription start site (TSS) of the gene, colored as a density plot. **c.** The mean effect size (beta) of chromatin accessibility on the gene expression in arthritis-tissue dataset within each bin of TSS distance. Left; all significant gene-peak links. Right; SCENT peaks within enhancers identified using chromHMM in immune-related tissues. **d**. Mean phastCons score difference (phastCons score) between each annotated region and all *cis*-regulatory non-coding regions. We show the phastCons score for exonic regions (purple) as a reference, and for SCENT (green) and all *cis*-ATAC peaks (yellow) enhancers in each multimodal dataset.

To assess if peaks (i.e., *cis*-regulatory regions) identified through SCENT were functional,

we examined if (1) they co-localized with conventional *cis*-regulatory annotation, (2) the effect of

peaks on expression was greater for closer peak-gene pairs, (3) SCENT peaks had high

sequence conservation, and (4) peak-gene connections were more likely to be validated

experimentally.

First, we tested how many of the SCENT peaks overlapped with an ENCODE cCRE[62], a

conventional *cis*-regulatory annotation defined by bulk-based epigenomic datasets. We

observed that 98.0% of the SCENT peaks overlapped with ENCODE cCRE on average,

compared to 23.3% of random *cis*-regions matched for size and 89.0% of non-SCENT peaks

(**Supplementary Figure 3c**).

Second, we examined the strength and direction of enhance-gene links, hypothesizing

that stronger links would be more proximal to the transcription start site (TSS) of target genes.

We observed that the regression coefficient β_{peak} (the effect size of peak accessibility on gene

expression) becomes larger and more positive as the SCENT *cis*-regulatory elements (peaks)

get closer to the TSS (**Figure 2b** and **Figure 2c,** left panel), consistent with previous

observations[56,63]. We annotated *cis*-regulatory regions identified by SCENT with 18-state

chromHMM results from 41 immune-related samples in ENCODE consortium[37]. When we

subset peaks to those within enhancer annotations, we observed a clearer decay in effect size

as a function of TSS distance (**Figure 2c,** right panel).

Third, we assessed whether SCENT peaks had higher sequence conversation across

species. We reasoned that SCENT captures functionally important and thus evolutionary

conserved regions. The evolutionary conserved regulatory regions are known to be enriched for

complex trait heritability[64]. We used evolutionary conservation metric, phastCons[65] to assess

sequence conservation at SCENT peaks. As expected, exonic regions were much more

evolutionary conserved than all non-coding *cis*-region (mean Δ phastCons score = 0.38, paired

t-test $P < 10^{-323}$; **Figure 2d**, purple). The SCENT regulatory regions were also conserved

relative to non-coding *cis*-regions (mean Δ phastCons score = 0.13, paired t-test $P = 4.2 \times 10^{-42}$

in arthritis-tissue dataset; **Figure 2d**, green). In contrast, the Δ phastCons score between all

cis-ATAC peaks and all non-coding *cis*-region was more modest (mean Δ phastCons score =

0.092, paired t-test $P = 8.7 \times 10^{-27}$ in arthritis-tissue dataset; **Figure 2d**, yellow). To test if the

higher conservation in SCENT peaks were driven by their proximity to TSS, we assessed Δ

phastCons score between SCENT peaks and non-SCENT peaks with matching peaks on TSS

distance. SCENT peaks had significantly higher conservation scores than the non-SCENT

peaks when we matched on TSS distance (mean Δ phastCons score = 0.034, $P = 4.7 \times 10^{-4}$ in

arthritis-tissue dataset; **Supplementary Figure 3d**; see **Methods**). The higher sequence

conservation suggested the functional importance of SCENT regulatory regions not solely

driven by TSS proximity.

Finally, we tested whether the target genes from SCENT were enriched for

experimentally confirmed enhancer-gene links. We used Nasser et al.[39] CRISPR-Flow FISH

results which included 278 positive enhancer-gene connections where perturbation decreased

connections, and 5,470 negative connections. We observed that the SCENT peaks were >

4-fold enriched relative to non-SCENT peaks for positive connections (4.5X, Fisher's exact

P=1.8x10^{-9}, arthritis-tissue dataset and 4.5X, P=1.0x10^{-8} in public PBMC dataset; **Methods,**

Supplementary Table 3).

We anticipate that the genes with the largest number of SCENT peaks are likely to be

the most constraint and least tolerant to loss of function mutations. The genes with the most

SCENT peaks per gene included *FOSB* (n = 97), *JUNB* (n = 95), and *RUNX1* (n = 77), critical

and highly conserved transcription factors. We used mutational constraint metrics based on the

absence of deleterious variants within human populations (i.e., the probability of being

loss-of-function intolerant (pLI) [66] and the loss-of-function observed/expected upper bound

fraction (LOEUF)[67]). We observed that the normalized number of SCENT *cis*-regulatory

elements per gene is strongly associated with mean constraint score for the gene (beta = 0.37,

P = 4.9x10^{-90} for pLI where higher score indicates more constraint, and beta = -0.35, P =

-0.35x10^{-106} for LOEUF where lower score indicates more constraint; **Supplementary Figure**

4a and **4b**, respectively). Previous results have shown that genes with many regulatory regions

based on bulk-epigenomic data had been enriched for loss-of-function intolerant genes[68]. We

were able to replicate the same trend by using the single-cell multimodal datasets and SCENT.

Enrichment of eQTL putative causal variants in SCENT peaks

We sought to examine whether the SCENT peaks are likely to harbor statistically fine-mapped

putative causal variants for expression quantitative loci (eQTL). We analyzed tissue-specific

eQTL fine-mapping results from GTEx consortium across 49 tissues[69]. We used statistical

fine-mapping results (posterior inclusion probability [PIP] > 0.2) to define putative causal

variants. We then tested enrichment statistics within ATAC peaks or SCENT peaks (see

Methods). Unsurprisingly, all the accessible regions defined by ATAC-seq in *cis*-regions were

modestly enriched in fine-mapped variants by 2.7X (yellow, **Figure 3a**). However, SCENT

peaks were more strikingly enriched in fine-mapped variants by 9.6X on average across all

datasets (green, **Figure 3a**). Using more stringent PIP threshold cutoffs (0.5 and 0.7) to define

putative causal variants resulted in even stronger enrichments (**Supplementary Figure 5**).

Since many SCENT peaks are close to TSS regions, we considered whether this

enrichment might be driven by TSS proximity (**Figure 2c**, **Supplementary Figure 6a**). To test

this, we matched each of the SCENT peak-gene pairs to one non-SCENT peak-gene pair that

had the most similar TSS distance (**Supplementary Figure 6b**). We compared the

fine-mapped variant enrichment between those two sets of peak-gene pairs with matched TSS

distance. We observed that SCENT peaks consistently had higher enrichment in all analyzed

datasets (**Supplementary Figure 6c**) than TSS-distance-matched non-SCENT peaks (e.g.,

12.3X in SCENT vs. 9.64X in distance-matched non-SCENT in arthritis-tissue dataset). This

suggests that SCENT has additional information in identifying biologically important

cis-regulatory regions beyond TSS distance.

Figure 3. SCENT enhancers are enriched in causal variants of eQTL and GWAS.
a. The mean causal variant enrichment for eQTL within SCENT peaks or all ATAC-seq peaks in each of the 9 single-cell datasets. The bars indicate 95% confidence intervals by bootstrapping genes. **b**. Comparison of the mean causal variant enrichment for eQTL (y-axis) between SCENT (green), ArchR (pink), and Signac (purple) as a function of the number of significant peak-gene pairs at each threshold of significance. The bars indicate 95% confidence intervals by bootstrapping genes. The ArchR results with > 100,000 peak-gene linkages are omitted, and full results are in **Supplementary Figure 6d**. **c** and **d**. The mean causal variant enrichment for GWAS within SCENT enhancers (green), all cis-ATAC peaks (yellow), ENCODE cCREs (pink), EpiMap enhancers across all groups (red) and ABC enhancers across all samples (blue). GWAS results were based on FinnGen (**c**) and UK Biobank (**d**). The bars indicate 95% confidence intervals by bootstrapping traits. **e**. The mean causal variant enrichment for FinnGen GWAS within intersection of SCENT enhancers and caQTL enhancers at each threshold of significance. The bars indicate 95% confidence intervals by bootstrapping traits.

We next compared the enrichment for eQTL causal variants in SCENT peaks to peaks

identified by linear parametric methods, ArchR[56] and Signac[50] using myeloid cells in the

arthritis-tissue dataset. ArchR and Signac peaks had substantially lower causal variant

enrichment for eQTL in blood (1.4X and 9.3X, respectively) compared to SCENT peaks (74.1X)

in arthritis-tissue dataset. By varying the thresholds to define significant peak-gene associations

(correlation r in ArchR and FDR in SCENT), we assessed the number of peak-gene pairs and

the causal variant enrichment for eQTLs within these peaks (**Figure 3b** and **Supplementary**

Figure 6d). Indeed, SCENT peaks consistently demonstrated higher causal variant enrichment

than ArchR peaks and Signac peaks.

SCENT can detect *cis*-regulatory regions in a cell-type-specific manner. We created

cell-type-specific enhancer-gene maps in four major cell types with > 5,000 cells across

datasets; for each cell type we took the union of per-cell-type SCENT enhancers across all

datasets. We observed that the cell-type-specific SCENT enhancers (e.g., SCENT B cell

peaks) were most enriched in putative causal eQTL variants within relevant samples in GTEx

(e.g., EBV-transformed lymphocytes; **Supplementary Figure 6e**).

These results suggest that SCENT can prioritize regulatory elements harboring putative

causal eQTL variants in a cell-type-specific manner, with higher precision than the previous

single-cell based method.

Enrichment of GWAS causal variants in SCENT enhancers

Given that the combination of SCENT and multimodal data from disease-relevant tissues can

be used to quickly build disease-specific enhancer-gene maps, we sought to examine whether

SCENT peaks can be used for the more difficult task of prioritizing disease causal variants. To

identify candidate causal variants (PIP>0.2), we used fine-mapping results from complex trait

loci from GWAS in two large-scale biobanks (FinnGen[70] [1,046 disease traits] and UK

Biobank[71] [35 binary traits and 59 quantitative traits])[28]. We defined enrichment statistics for

GWAS causal variants within SCENT enhancers (see **Methods**). The SCENT enhancers were

strikingly enriched in causal GWAS variants in FinnGen (31.6X on average; 1046 traits; **Figure**

3c and **Supplementary Figure 7a**) and UK Biobank (73.2X on average; 94 traits; **Figure 3d**

and **Supplementary Figure 7b**). This enrichment was again much larger than all *cis*-ATAC

peaks (12.8X in FinnGen and 38.8X in UK Biobank). Moreover, the target genes of causal

variants for autoimmune diseases (AID) identified by SCENT enhancer-gene map in

immune-related cell types had higher fraction (10.8%) of know genes implicated in Mendelian

disorders of immune dysregulation (n_{gene} = 550)[72,73] than SCENT enhancer-gene map in

fibroblast (3.8%; **Supplementary Figure 7c**).

We compared SCENT to other alternative genome annotations and enhancer-gene

maps that have recently emerged. Causal variant enrichment in SCENT was much higher than

the conventional bulk-based annotations such as ENCODE cCREs (13.9X in FinnGen and

46.5X in UK Biobank), ABC (16.3X in FinnGen and 53.3X in UK Biobank) and EpiMap, (12.9X

in FinnGen and 40.6X in UK Biobank; **Figure 3c** and **3d, Supplementary Figure 7a** and **b)**.

We varied thresholds to assess recall and precision tradeoffs (FDR in SCENT, ABC score in

ABC model and EpiMap correlation score in EpiMap) for identifying causal GWAS variants

(**Supplementary Figure 8a**). We constructed SCENT from 9 datasets with only 28 samples,

substantially less than the 833 samples used to construct EpiMap and 131 samples for the ABC

model. Despite this, SCENT peaks consistently demonstrated higher enrichment of causal

GWAS variants at a similar number of identified peak-gene linkages than ABC model and

EpiMap. A more stringent PIP threshold (0.5 and 0.7) to define putative causal variants further

increased the enrichment statistics while maintaining the higher enrichment in SCENT than bulk

methods (**Supplementary Figure 8b**). We tested whether causal genes are being identified by

examining a set of known genes implicated in Mendelian disorders of immune dysregulation.

We observed that the target genes for AID identified by SCENT enhancer-gene map in

immune-related cell types had higher fraction (10.8%) of implicated known Mendelian genes

[72,73] than EpiMap (8.6%) and ABC model (4.4%) enhancer-gene map (**Supplementary Figure**

7c). These results demonstrate the power SCENT achieved by accurately modeling association

between chromatin accessibility and gene expression at the single-cell resolution.

We hypothesized that disease-causal variants prioritized by SCENT would likely

modulate chromatin accessibility (e.g., transcription factor binding affinity). If so, the intersection

of the SCENT enhancers and chromatin accessibility quantitative trait loci (caQTL) could further

enrich the causal GWAS variants[74–77]. To test this hypothesis, we used single-cell ATAC-seq

samples with genotype (n_{donor} = 17; arthritis-tissue dataset) from the same tissue and performed

caQTL mapping by leveraging allele-specific (AS) chromatin accessibility (binomial test

followed by meta-analysis across donors) or by combining AS with inter-individual differences

(RASQUAL[78]; see **Methods**). We then defined caQTL ATAC peaks with variable thresholds

and intersected them with the SCENT enhancers. We calculated the causal GWAS variant

enrichment within these intersected regions. We observed drastically higher enrichment of

causal variants as we used more stringent threshold in defining caQTL peaks, reaching as high

as 333-fold enrichment (**Figure 3e**). This suggested that SCENT efficiently prioritized causal

GWAS variants in part by capturing regulatory regions of which chromatin accessibility is

perturbed by genetic variants and modulates gene expression. SCENT demonstrated a

potential to further enrich causal variants by using caQTLs if the multimodal data has matched

genotype data.

Defining mechanisms of GWAS loci by SCENT

We finally sought to use SCENT enhancer-gene links to define causal mechanisms of complex

trait GWAS. We used the fine-mapped variants from GWASs (FinnGen, UK Biobank traits and

GWAS fine-mapping results of rheumatoid arthritis (RA)[26], inflammatory bowel disease[29] and

type 1 diabetes (T1D)[79]). SCENT linked 4,124 putative causal variants (PIP > 0.1) to their

potential target genes across 1,143 traits in total (**Supplementary Table 4**).

We first focus on autoimmune loci, given that our current SCENT tracks are largely

derived from immune cell types and inflammatory tissues. We prioritized a single well

fine-mapped variant rs72928038 (PIP > 0.3) at 6q15 locus in multiple autoimmune diseases

(RA, T1D, atopic dermatitis and hypothyroidism), within the T-cell-specific SCENT enhancer (T

cells in Public PBMC datasets and Dogma-seq control and stimulated T cells; **Figure 4a**). This

enhancer was linked to *BACH2*, which was also the closest gene to this fine-mapped variant.

Notably, base-editing in T cells has confirmed that this variant affects *BACH2* expression[80].

Moreover, editing of this variant into CD8 T cells skewed naive T cells toward effector T cell

fates[80].

Figure 4. SCENT defined causal variants and genes in complex trait GWAS.
a. Rs72928038 at *BACH2* locus was prioritized by T-cell-specific SCENT enhancer-gene map, being for RA, T1D, Atopic dermatitis and hypothyroidism. The top four panels are GWAS

regional plots, with x-axis representing the position of each genetic variant. The color of the dots
represent LD r^2 from the prioritized variant (highlighted by light blue stripe). ATAC-seq and
SCENT tracks represent aggregated ATAC-seq tracks (top) and SCENT peaks (bottom with
grey stripes) in each cell type (public PBMC dataset for immune cell types and arthritis-tissue
dataset for fibroblast). An arrow head indicates the SCENT peak overlapping with fine-mapped
variant. **b**. Rs35944082 for RA and T1D was prioritized and connected to *RBPJ* by long-range
interaction from T-cell- and fibroblast- SCENT enhancer-gene map using inflamed synovium in
arthritis-tissue dataset. The top two panels are GWAS regional plots similarly to panel **a**.
ATAC-seq and SCENT tracks are shown similarly to panel **a**, but using both public PBMC and
arthritis-tissue datasets. **c**. Rs11031006 was prioritized and connected to *FSHB* for multiple
gynecological traits by using pituitary-derived single-cell multimodal dataset. The top four
panels are GWAS regional plots similarly to panel **a**. ATAC-seq and SCENT tracks are shown
similarly to panel **a**, and include tracks from pituitary dataset. There were no SCENT peaks in
cell types except for pituitary. **d**. ATAC-seq and SCENT tracks for *IL10RA* locus, where
non-coding ClinVar variants (grey dots) colocalized with T-cell SCENT track. **e**. ATAC-seq and
SCENT tracks for *CXCR4* locus, where somatic mutation hotspot for leukemia colocalized with
T-cell and myeloid-cell SCENT tracks.

Another locus for RA and T1D at chr 4p15.2 harbored 21 candidate variants, each with

low PIPs (< 0.14). SCENT prioritized a single variant rs35944082 in T cells and fibroblasts only

within the arthritis-tissue dataset from inflamed synovial tissue (**Figure 4b**). SCENT linked this

variant to *RBPJ*, which was the 3rd closest gene to this variant located 235kb away. This

variant-gene link was supported by a physical contact from promotor-capture Hi-C contact data

measured in hematopoietic cells[81]. *RBPJ* (recombination signal binding protein for

immunoglobulin kappa J region) is a transcription factor critical for NOTCH signaling, which has

been implicated in RA tissue inflammation through functional studies[82,83]. *Rbpj* knockdown in

mice resulted in abnormal T cell differentiation and disrupted regulatory T cell phenotype[84,85],

consistent with a plausible role gene in autoimmune diseases. Intriguingly, we observed no

SCENT peaks in T cells from PBMC or blood to prioritize causal variants at this locus. This

linkage was not present in EpiMap. ABC map prioritized another variant, rs7441808 at this

locus and linked it non-specifically to 16 genes including *RBPJ*, making it difficult to define the

true causal gene.

In a final example, we highlight the value of using SCENT to build enhancer-gene maps

from disease-critical tissues. We examined the enhancer-gene map produced from single-cell

multimodal pituitary data[61] to assess the 11p14.1 locus for multiple gynecological traits

(endometriosis, menorrhagia, ovarian cyst and age at menopause). Our map connected

rs11031006 to *FSHB* (follicle stimulating hormone subunit beta) (**Figure 4c**), which is

specifically expressed in the pituitary[69,86] and enables ovarian folliculogenesis to the antral

follicle stage[87]. Rare genetic variants within *FSHB* are known to cause autosomal recessive

417 hypogonadotropic hypogonadism[88]. However, the other multimodal datasets and bulk-based

418 methods (ABC model and EpiMap) were unable to prioritize and connect this variant to *FSHB*.

419 *FSHB* example showed the potential of SCENT for defining causal variants and genes by being

420 applied to disease-relevant tissues.

422 *Mendelian-disease variants and somatic mutations in cancer within SCENT enhancers*

423 Having established the SCENT's utility in defining causal variants and genes in complex

424 diseases, we examined rare non-coding genetic variants causing Mendelian diseases.

425 Currently, causal mutations and genes can only be identified in ∼30–40% of patients with

426 Mendelian diseases [89–91]. Consequently, many variants identified in case individuals are

427 annotated as variants of uncertain significance (VUS). The VUS annotation is especially

428 challenging for non-coding variants. We asked whether our SCENT enhancers overlapped with

429 clinically reported non-benign non-coding variants by ClinVar[92] (400,300 variants in total). The

430 SCENT enhancers harbored 2.0 times ClinVar variants on average than all the ATAC regions

431 with the same genomic length across all the datasets we investigated (**Supplementary Figure**

432 **9**). This density of ClinVar variants was 3.2 times and 12 times on average larger than that in

433 ENCODE cCREs and of all non-coding regions, respectively. We thus defined 3,724 target

434 genes for 33,618 non-coding ClinVar variants by SCENT in total (**Supplementary Table 5**). As

435 illustrative examples, we found 40 non-coding variants linked to *LDLR* gene causing familial

436 hypercholesterolemia 1[92], 3 non-coding variants linked to *IL10RA* causing autosomal recessive

early-onset inflammatory bowel disease 28 (**Figure 4d**)[93], and an intronic variant rs1591491477

linked to *ATM* gene causing hereditary cancer-predisposing syndrome[92].

Finally, we used SCENT to connect non-coding somatic mutation hotspots to target

genes. Recently, somatic mutation analyses across the entire cancer genome revealed

possible driver non-coding events[94]. Among 372 non-coding somatic hotspots in 19 cancer

types, SCENT enhancers included 193 cancer-mutation hotspot pairs (**Supplementary Table**

6). SCENT enhancer-gene linkage successfully linked those hotspots to known driver genes

(e.g., *BACH2*, *BCL6*, *BCR*, *CXCR4* (**Figure 4e**), and *IRF8* in leukemia). In some instances,

SCENT nominated different target genes for those mutation hotspots from those based on ABC

model used in the original study. For example, SCENT connected a somatic mutation hotspot in

leukemia at chr14:105568663-106851785 to *IGHA1* (Immunoglobulin Heavy Constant Alpha 1)

which might be more biologically relevant than *ADAM6* nominated by ABC model. These results

implicate broad applicability of SCENT for annotating all types of human variations in

non-coding regions.

Augmenting SCENT enhancer-gene maps with more samples

While the recall for enhancer-gene maps defined by SCENT was lower than that by

bulk-tissue-based methods, we felt that this might be a function of current limited sample sizes.

We wanted to assess if the addition of more cells into SCENT might lead to the higher recall for

enhancer-gene maps while retaining the precision. To assess this, we downsampled our

multimodal single cell dataset. We observed that the number of significant gene-peak pairs

increased linearly to the number of cells per cell type in a given dataset, suggesting that SCENT

will be even better powered as the size of sc-multimodal datasets increases (**Supplementary**

Figure 10). We considered the possibility that enhancer-gene maps with greater numbers of

cells might capture spurious associations; if this was the case, we would expect more

long-range associations, which are more likely to be false positives with greater cell numbers. In

contrast, we observed that shorter-range and longer-range associations were both equivalently

represented as we added additional cells, suggesting the robustness of our discovery.

Discussion

In this study, we presented a novel statistical method, SCENT, to create a cell-type-specific

enhancer-gene map by using single-cell multimodal data. Single-cell RNA-seq and ATAC-seq

are both sparse and have variable count distributions, which requires non-parametric

bootstrapping to connect chromatin accessibility with gene expression. The SCENT model

demonstrated well-controlled type I error, outperforming commonly used statistical models

which showed inflated statistics. SCENT mapped enhancers that showed strikingly high

enrichment for putative causal variants in eQTLs and GWASs and outperformed previous

methods analyzing single-cell multimodal data (e.g., ArchR[49] and Signac[50]). Despite using

substantially lower number of samples (28 from 9 datasets in total), enhancers defined by

SCENT had equivalent or even higher enrichment for causal variants than bulk-tissue-based

methods with more than 100 samples (e.g., EpiMap and ABC model), by modeling single-cell

level observations instead of obscuring them into sample-level association.

As potential limitations, first, our enhancer-gene maps had relatively fewer enhancers

identified compared to other resources (**Figure 2a**). However, downsampling experiments

showed a clear linear relationship between the number of cells per cell type per dataset and the

number of significant SCENT peak-gene links. It follows that SCENT applied to larger datasets

from a diverse set of tissues will further expand the current enhancer-gene map. In contrast,

bulk-tissue-based enhancer-gene map might have an upper limit of discovery by the number of

samples generated by each consortium (e.g., ENCODE). Second, SCENT focuses on gene

cis-regulatory mechanisms to fine-map disease causal alleles, while there could be other

causal mechanisms that explain disease heritability, such as alleles that act through

trans-regulatory effects, splicing effects, or post-transcriptional effects[95].

We argue that the real utility of SCENT is that it enables the rapid construction of

disease-tissue-relevant enhancer-gene maps. Multimodal single cell data can be easily

obtained from a wide range of primary human tissues. Since these assays query nuclear

material, data can be obtained without disaggregating tissues. Hence, the data is likely robust

to the effects of disaggregation which is employed for assays that need intact cells from tissue.

Therefore, it is possible to build relevant tissue-specific enhancer-gene maps that are

necessary to understand the causal mechanisms of common diseases from GWAS, rare

diseases from mapping Mendelian diseases, and somatic non-coding mutations in cancers. For

example, understanding the *FSHB* locus in gynecological traits specifically required a pituitary

map, and *RBPJ* locus in RA specifically required a synovial tissue map.

In summary, our method SCENT is a robust, versatile method to efficiently define causal

variants and genes in human diseases and will fill the gap in the current enhancer-gene map

built from genomic data in bulk tissues.

Data Availability

The publicly available datasets were downloaded via Gene Expression Ombibus (accession

codes: GSE140203, GSE156478, GSE178707, GSE193240, GSE178453) or web repository

(https://www.10xgenomics.com/resources/datasets?query=&page=1&configure%5Bfacets%5D

%5B0%5D=chemistryVersionAndThroughput&configure%5Bfacets%5D%5B1%5D=pipeline.ve

rsion&configure%5BhitsPerPage%5D=500&menu%5Bproducts.name%5D=Single%20Cell%2

0Multiome%20ATAC%20%2B%20Gene%20Expression,

https://openproblems.bio/neurips_docs/data/dataset/). The raw data for arthritis-tissue dataset

(single-cell multimodal RNA/ATAC-seq and single-cell ATAC-seq) will be publicly available

before the acceptance of this manuscript.

Code Availability

The   computational   scripts   related   to   this   manuscript   are   available   at

https://github.com/immunogenomics/SCENT.

Methods

Data and sample in arthritis-tissue dataset

This study was performed in accordance with protocols approved by the Brigham and Women's

Hospital and the Hospital for Special Surgery institutional review boards. Synovial tissue from

patients with RA and OA were collected from synovectomy or arthroplasty procedures followed

by cryopreservation as previously described[96]. RA samples with high levels of lymphocyte

infiltration (as scored by a pathologist on histologic sections) were identified as "inflamed" and

used for downstream analysis. Next, cryopreserved synovial tissue fragments were dissociated

by a mechanical and enzymatic digestion[96], followed by flow sorting to enrich for live synovial

cells. For each tissue sample, 15,000 viable cells were isolated and lysed to extract nuclei

according to manufacturer protocol (10X Genomics). Joint sc-RNA- and sc-ATAC-seq libraries

were prepared using the 10x Genomics Single Cell Multiome ATAC + Gene Expression kit

according to manufacturer's instructions. Libraries were sequenced with paired-end 150-bp

reads on an Illumina Novaseq to a target depth of 20,000 read pairs per nuclei for mRNA

libraries and 25,000 read pairs per nucleus for the ATAC libraries. Demultiplexed scRNA-seq

fastq files were inputted into the Cell Ranger ARC pipeline (version 2.0.0) from 10x Genomics

to generate barcoded count matrix of gene expression. For ATAC-seq, we trimmed adaptor and

primer sequences and mapped the trimmed reads to the hg38 genome by BWA-MEM with

default parameters. To deduplicate reads from PCR amplification bias within a cell while

keeping reads originating from the same positions but from different cells, we used in-house

scripts (manuscript in preparation).

Uniform processing of single-cell multimodal datasets

In addition to our arthritis-tissue multimodal dataset, we downloaded all publicly available

multimodal RNA-seq/ATAC-seq datasets from adult human tissues ($n_{dataset}$ = 9, as of April

2022). We processed these downloaded count matrices of gene expression and ATAC data.

Briefly, we applied QC to both the nuclear RNA data and the ATAC data based on RNA counts,

ATAC fragments, nucleosome signal, and TSS enrichment (**Supplementary Table 7**). We only

kept cells that had passed QC in both RNA-seq and ATAC-seq. Then to identify open chromatin

regions (peaks), we used macs2 to call open chromatin peaks using post-QC ATAC-seq data.

We thus obtained count matrices of gene expression and ATAC peaks with corresponding cell

barcodes. Gene expression counts were normalized using the NormalizeData function

(Seurat[97]), scaled using the ScaleData function (Seurat), and batch corrected using Harmony[98].

We visualized the cells in two low-dimensional embeddings with UMAP by using 20

batch-corrected principal components from these normalized gene expression matrices (**Figure**

1c). When original cell labels are provided by the authors, we used those labels to obtain broad

cell type categories. When they are not available, we performed reference-query mapping by

Seurat and PBMC reference object to define broad cell type labels. ATAC peak matrix was

binarized to have 1 if a count is > 0 and 0 otherwise.

SCENT method

We defined *cis*-peaks as any peaks whose center is within the window +/-500 bp from the target

gene's TSS. We modeled the association between peak's binarized accessibility and the target

gene's expression with Poisson distribution:

$$E_i \sim Poisson(\lambda_i)$$

$$log(\lambda_i) = \beta_0 + \beta_{peak}X_{peak} + \beta_{\%mito}X_{\%mito} + \beta_{nUMI}X_{nUMI} + \beta_{batch}X_{batch}$$

where E_i is the observed expression count of ith gene, and λ_i is the expected count under

Poisson distribution. β_{peak} indicates the effect of chromatin accessibility of a peak on i th

gene expression. $\beta_{\%mito}$, β_{nUMI}, and β_{batch} each represents the effect of covariates,

percentage of mitochondrial reads per cell as a mesure of cell quality, the number of UMIs in

the cell, and the batch, respectively. To assess significance of β_{peak}, we used bootstrapping

procedures, where we resampled cells with replacement in each procedure and estimate

β'_{peak} within those cells. To reduce computational burden, we adaptively increased the number

of from at least 100 and up to 10,000, depending on the significance of β_{peak} in each chunk of

bootstrapping trials. To avoid spurious associations from rare ATAC peak and rare gene

expression, we QCed cis-peak-gene pairs we test so that both peak and gene should have

been expressed in at least 5% of the cells we analyze. We finally defined a set of significant

peak-gene pairs for each cell type based on FDR (Benjamini & Hochberg correction).

575   When we tested the calibration of statistics from SCENT or other regression strategies

(**Supplementary Figure 1**), we used null dataset where we randomly permuted cell labels in

the ATAC-seq and ran the regression model we tested.

ArchR peak2gene and Signac LinkPeaks method

We analyzed arthritis-tissue dataset with ArchR[49] and Signac[50] for single-cell multimodal data,

which both have a function to define peak-gene linkages. In brief, ArchR takes multimodal data

and creates low-overlapping aggregates of single cells based on *k*-nearest neighbor graph.

Then it correlates peak accessibility with gene expression by Pearson correlation of aggregated

and log2-normalized peak count and gene count. Signac computes the Pearson correlation

coefficient *r* (corSparse function in R) for each gene and for each peak within 500kb of the gene

TSS. Signac then compares the observed correlation coefficient with an expected correlation

coefficient for each peak given the GC content, accessibility, and length of the peak. Signac

defines *P* value for each gene-peak links from the z score based on this comparison. We ran

both methods on arthritis-tissue dataset with default parameters. We output statistics for all

peak-gene pairs we tested without any cut-off for correlation *r* or *P* values. We used FDR in the

output from ArchR software, or computed FDR using *P* values in the output from Signac

software by Benjamini & Hochberg correction. We defined significant peak-gene linkages as

those with FDR < 0.10, and used varying correlation *r* to assess the precision and recall in the

causal variant enrichment analysis (see later sections in **Method**).

Replication across datasets

Since we have the same immune-related cell types across different multimodal datasets, we

evaluated the concordance of enhancer-gene map in a discovery dataset (arthritis-tissue

dataset) when compared with other replication datasets including immune-related cell types

(Public PBMC, NeurIPS, SHARE-seq and NEAT-seq datasets). To this end, we used most

stringent FDR threshold for defining an enhancer-gene map in arthritis-tissue dataset (FDR <

1%). We then used more lenient threshold for defining an enhancer-gene map in replication

datasets (FDR < 10%), which is a similar strategy used in assessing replication in GWAS. For

each cell type and for each replication dataset, we took the intersection of enhancer-gene links

defined as significant in both datasets. We assessed the directional concordance (i.e.,

concordance of the sign of β_{peak}) and the Pearson's correlation r of β_{peak} between the

discovery and the replication for these peak-gene pairs. For the largest replication dataset of

Public PBMC, we performed the same analysis for enhancer-gene map from ArchR and Signac

software.

Conservation score analysis

To compare the evolutional conservation across species between our annotated peaks and the

other peaks, we used phastCons[65] score. We downloaded the phastCons score for multiple

alignments of 99 vertebrate genomes from

https://hgdownload.cse.ucsc.edu/goldenpath/hg19/phastCons100way/. We lifted them over to

GRCh38 by LiftOver software. We used SCENT results for arthritis-tissue, Public PBMC and

NeurIPS for conservation score analysis as representative datasets with the largest numbers of

cells. Because each gene should have variable functional importance and conservation, we

assessed each gene separately. For each gene, we took (1) an annotation of interest for the

gene and (2) all *cis*-non-coding regions (< 500kb from a gene), and computed the mean

phastCons score of each of two sets of the peaks. As annotations to be tested, we used a.

exonic regions of the gene, b. SCENT peaks for the gene, and c. all ATAC peaks in cis-regions

from the gene (< 500 kb). Then, we took the difference between two mean differences

(Δ phastCons score), and computed the mean differences across all the genes

(mean Δ phastCons score) as follows.

$$\text{mean } \Delta \text{ phastCons score} = \frac{1}{n_{gene}} \sum_{gene} \overline{(phastCons_{g,in\_annot}} - \overline{phastCons_{g,non-coding})}$$

626   By bootstrapping the genes, we calculated the 95% CI of the mean Δ phastCons score.

627   If this metric is positive, that indicates that the annotated regions are more conserved than

628   non-coding regions.

629   We also calculated similar Δ phastCons score by comparing the SCENT peaks with

630   TSS-distance-matched non-SCENT peaks in each dataset.

$$\text{mean } \Delta \text{ phastCons score}$$
$$= \frac{1}{n_{gene}} \sum_{gene} \overline{(phastCons_{g,peak\_in\_SCENT}} - \overline{phastCons_{g,peak\_non\_SCENT\_matched})}$$

By bootstrapping the genes, we again calculated the 95% CI of the mean Δ phastCons

score. If this metric is positive, that indicates that SCENT peaks are more conserved than

TSS-distance-matched non-SCENT peaks.

Construction of a set of TSS-matched non-SCENT peaks

To assess the effect of TSS distance when comparing SCENT peaks with non-SCENT peaks,

we matched each one of the SCENT peak-gene pairs to one non-SCENT peak-gene pair,

where the peak had the most similar TSS distance to the same gene among all the ATAC peaks

in *cis* in each of the dataset. We confirmed that the resulting TSS-distance-matched

non-SCENT peak-gene pairs demonstrated the similar distributions of TSS distance when

compared with the SCENT peak-gene pairs (**Supplementary Figure 5b**).

Gene's constraint and the number of significant SCENT peaks for a gene

We sought to investigate the relationship between the number of significant SCENT peaks for

each gene and the gene's evolutionary constraint. We used pLI and LOEUF as metrics for the

gene's loss-of-function intolerance within human population. We downloaded both pLI and

LOEUF scores from gnomAD browser (https://gnomad.broadinstitute.org/downloads). We

inverse-normal transformed the raw number of significant SCENT peaks for each gene, since

the raw number of significant SCENT peaks for each gene is rightly skewed (**Supplementary**

Figure 3a). We performed linear regression between the normalized number of significant

SCENT peaks and pLI or LOEUF score with accounting for gene length, which could be

potential confounding factor for pLI and LOEUF[66,67].

Validation with CRISPR-Flow FISH results

To validate our SCENT enhancer-gene links, we used published CRISPR-Flow FISH

experiments as potential ground-truth positive enhancer element-gene links and negative

enhancer element-gene links. We downloaded the experimental results from the

Supplementary Table 5 of original publication[39]. We used "Perturbation Target" as candidate

enhancer elements. We defined 283 positive enhancer element-gene links when they are

"TRUE" for "Regulated" column (i.e., the element-gene pair is significant and the effect size is

negative) and 5,472 negative enhancer element-gene links when they are "FALSE" for

"Regulated" column. We lifted them over to GRCh38 and obtained final sets of 278 positive

links and 5,470 negative links.

We used two most powered datasets, arthritis-tissue and Public PBMC datasets. For

each dataset, we used "bedtools intersect" to categorize SCENT peak-gene links and

non-SCENT ATAC peak-gene pairs into either CRISPR-positive or CRISPR-negative groups,

based on whether these peaks overlapped with positive or negative CRISPR-Flow FISH links

for the same gene (**Supplementary Table 3**). We finally performed two-sided Fisher's exact

test to assess the enrichment of CRISPR-positive links within SCENT peak-gene links in each

dataset.

Cell-type-specific SCENT tracks and aggregated SCENT tracks

For cell types with more than 5,000 cells across datasets, we concatenated SCENT peak-gene

linkages across all the datasets to create cell-type-specific SCENT tracks. We collected a set of

SCENT peak-gene linkages for the same cell type and used "bedtools merge" function (for each

gene) to obtain a union of SCENT peaks for each gene. Similarly, we created aggregated

SCENT tracks across all the cell types and all datasets. We collected all sets of SCENT

peak-gene linkages and used "bedtools merge" function (for each gene) to obtain a union of

SCENT peaks for each gene across all the cell types and all datasets.

Causal variant enrichment analysis using eQTLs

We defined a causal enrichment for eQTL within SCENT enhancers and other annotations by

using statistically fine-mapped variant-gene combinations from GTEx. We used publicly

available statistics analyzed by CAVIAR software[20], and selected variants with PIP > 0.2 as

putatively causal (fine-mapped) variants for primary analyses. For the primary enrichment

analysis, we aggregated fine-mapped variants from all the 49 tissues. For cell-type-specific

SCENT enrichment analysis (**Supplementary Figure 6e**), we used fine-mapped variants from

each tissue separately. We intersected these putatively causal variants with our annotation

(SCENT peaks, ArchR peaks or Signac peaks). We then retained any variants which the linking

method (SCENT, ArchR and Signac) connected to the same gene as GTEx phenotype gene.

$$Enrichment_{gene\_i} = \frac{\# \, causal\_var\_in\_annot_{gene\_i} \Big/ \sum common\_var\_in\_annot_{gene\_i}}{\# \, causal\_var_{gene\_i} \Big/ \sum common\_var\_in\_cis_{gene\_i}}$$

$$Overall\_Enrichment = \frac{1}{n}\sum_{i=1}^{n} Enrichment_{gene\_i}$$

For each gene i (expression phenotype), we divided the number of putatively causal variants

within an annotation normalized by the number of common variants within an annotation by the

number of all causal variants for gene i normalized by the number of all common variants

within cis-region from for gene i. To calculate common variants within annotation or within

locus, we used 1000 Genomes Project genotype. We selected any variants with minor allele

frequency > 1% in European population as a set of common variants to be intersected with

each annotation. To derive $Overall\_Enrichment$ score, we took the mean across all the genes.

To have further insights into precision and recall and compare against ArchR peak2gene

and Signac LinkPeaks functions, we varied the threshold for defining a set of significant

peak-gene linkages in each software (i.e., FDR in SCENT {0.50, 0.30, 0.20, 0.10, 0.05, 0.02},

Peason's correlation r {any, 0, 0.1, 0.3, 0.5, 0.7} in ArchR, and correlation socre {any, 0, 0.05,

0.1, 0.15} in Signac). We then used each set of peak-gene linkages to re-calculate causal

variant enrichment $Overall\_Enrichment$ score (**Figure 3b**).

We also assessed the impact of PIP threshold in defining a set of statistically

fine-mapped variants on the causal variant enrichment analysis. To do so, we re-defined the set

of putative causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and

re-computed the calculate causal variant enrichment $Overall\_Enrichment$ score.

GWAS fine-mapping results

We used GWAS fine-mapping results in FinnGen release 6[70] upon registration and publicly

available GWAS fine-mapping results in UK Biobank[71] (https://www.finucanelab.org/data). For

FinnGen traits, we downloaded all the fine-mapping results by SuSIE software[22] and

systematically selected any traits with case count > 1,000. We then selected non-coding

fine-mapped loci which did not include any non-synonymous or splicing variants with PIP > 0.5.

We thus analyzed 1,046 traits and 5,753 loci in total after QC. For UK Biobank, we analyzed the

fine-mapping results by SuSIE software for all 94 traits including binary and quantitative traits.

Since the genomic coordinates for the UK Biobank fine-mapping results were hg19, we lifted

them over to GRCh38 by using LiftOVer software. We again selected non-coding fine-mapped

loci which did not include any non-synonymous or splicing variants with PIP > 0.5. We thus

analyzed 7,274 loci in total after QC.

We analyzed three additional autoimmune GWAS fine-mapping results for RA[26], T1D[79],

and IBD[29], given our special interest in immune-mediated traits. We similarly selected

non-coding fine-mapped loci which did not include any non-synonymous or splicing variants

with PIP > 0.5, and lifted the results over to GRCh38 by using LiftOVer software. We defined

117 loci for RA, 77 loci for T1D and 86 loci for IBD.

Causal variant enrichment analysis using GWASs

We defined a causal enrichment for GWAS within SCENT enhancers and other annotations by

using statistically fine-mapped variants from FinnGen[70] and UK Biobank[71] which we described

in the previous section. We selected variants with PIP > 0.2 as putatively causal variants for

primary analyses.

$$Enrichment_{trait\_i} = \frac{\#\ causal\_var\_in\_annot_{trait\_i} \Big/ \sum common\_var\_in\_annot_{trait\_i}}{\#\ causal\_var_{trait\_i} \Big/ \sum common\_var\_across\_loci_{trait\_i}}$$

$$Overall\_Enrichment = \frac{1}{n} \sum_{i=1}^{n} Enrichment_{trait\_i}$$

For each trait i, we divided the number of putatively causal variants within an annotation

(across all loci for trait i) normalized by the number of common variants within an annotation by

the number of all causal variants for trait i normalized by the number of all common variants

within all significant loci analyzed for the trait i. To calculate common variants within annotation

or within locus, we again used 1000 Genomes Project variants with minor allele frequency > 1%

in European population. To derive $Overall\_Enrichment$ score, we took the mean across all the

traits.

Comparison with bulk-tissue-based regulatory annotation and enhancer-gene maps

We downloaded per-group EpiMap enhancer-gene links from

https://personal.broadinstitute.org/cboix/epimap/links/pergroup/. We lifted the genomic

coordinates to GRCh38 by using LiftOver software. When we assessed aggregated EpiMap

enhancer-gene links across all the groups, we used "bedtools merge" function for each gene to

create a union of all enhancer-gene links. To benchmark the precision and recall, we used

EpiMap correlation scores to define variable sets of enhancer-gene links from EpiMap based on

the threshold of EpiMap correlation score.

We downloaded ABC predictions in 131 cell types and tissues from

ftp://ftp.broadinstitute.org/outgoing/lincRNA/ABC/AllPredictions.AvgHiC.ABC0.015.minus150.F

orABCPaperV3.txt.gz. We lifted the genomic coordinates to GRCh38 by using LiftOver software.

When we assessed cell-type-specific ABC model with SCENT enhancers, we aggregated cell

lines or cell types to be corresponding with our cell types (B cell, T cell, Myeloid cells, and

fibroblasts). When we assessed aggregated ABC enhancer-gene links across all the groups,

we used "bedtools merge" function for each gene to create a union of all enhancer-gene links.

To benchmark the precision and recall, we used ABC scores to define variable sets of

enhancer-gene links from ABC model based on the threshold of ABC score.

To assess precision and recall and compare against bulk-tissue based methods (i.e.,

EpiMap and ABC model), we used sets of significant peak-gene linkages in each method with

varying thresholds (i.e., FDR in SCENT {0.5, 0.3, 0.2, 0.1, 0.05, 0.02}, EpiMap score {0, 0.4, 0.8,

0.9} in EpiMap, and ABC score {0, 0.05, 0.1, 0.2} for ABC model). We then used each set of

peak-gene linkages to re-calculate causal variant enrichment for GWAS (**Figure 3d**).

We also assessed the impact of PIP threshold in defining a set of statistically

fine-mapped variants on the causal variant enrichment analysis. To do so, we re-defined the set

of putative causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and

re-computed the calculate causal variant enrichment $Overall\_Enrichment$ score.

caQTL analysis using scATAC-seq samples with genotype

We used independent arthritis-tissue dataset with single-cell unimodal ATAC-seq data with

genotype (*n* = 17, *manuscript in preparation*) to define chromatin accessibility QTLs (caQTLs).

We used two methods, binomial test and RASQUAL. Briefly, we genotyped donors by using

Illumina Multi-Ethnic Genotyping Array. We performed quality control of genotype by sample

call rate > 0.99, variant call rate > 0.99, minor allele frequency > 0.01, and $P_{HWE} > 1.0 \times 10^{-6}$.

We performed haplotype phasing with SHAPEIT2 software[99] and performed whole-genome

imputation by using minimac3 software[100] with a reference panel of 1000 Genomes Project

phase 3[101]. After imputation, we selected variants with imputation $Rsq > 0.7$ as post-imputation

QC. We next created a merged bam file of ATAC-seq for each donor and each cell type by

aggregating all the reads. Using the imputed genotype for each donor and aggregated bam files

for each donor and cell type, we applied WASP[102] to correct any bias in read mapping toward

reference alleles to accurately quantify allelic imbalance. We thus created a bias-corrected bam

files for each donor and cell type.

For binomial tests, we ran ASEReadCounter module in GATK software[103] using the

bias-corrected bam files as input to quantify allelic imbalance in heterozygous sites with read

count > 4 within ATAC peak counts. We first performed one-sided binomial tests in each donor,

and meta-analyzed the statistics across donors by Fisher's method if multiple donors shared

the same heterozygous site. For RASQUAL, we created a VCF file containing both genotype

dosage and allelic imbalance from ASEReadCounter. We quantified the read coverage for each

peak and for each donor by "bedtools coverage" function. We created a peak by donor matrix

with read coverage. We QCed samples with log(total mapped fragments) fewer than mean –

2SD across samples in each cell type. We QCed peaks so that at least two individuals have any

fragments for the peak. We then ran RASQUAL software with the inter-individual differences in

ATAC peak counts (in a peak by donor matrix) and intra-individual allelic imbalance (in VCF),

with accounting for chromatin accessibility PCs (the first N components whose explained

variances are greater than those from permutation result), 3 genotype PCs, sample site and sex

as covariates. RASQUAL output chi-squared statistics and P values. We computed FDR from

these raw *P* values by Benjamini & Hochberg correction on local multiple test burden (i.e., the

number of *cis*-SNPs in the region). To correct for genome-wide multiple testing, we ran the

RASQUAL with random permutation, where the relationship between sample labels and the

count matrix was broken. Thus, we derived *q* values for each candidate caQTL.

We finally intersected these peaks with significant caQTL effect in each significance

threshold with SCENT peaks and assessed causal variants enrichment within these peaks for

GWAS as explained in the previous sections.

ClinVar analysis

We downloaded the latest clinically reported variant list registered at ClinVar from

https://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh38/clinvar.vcf.gz. We then screened the

variants to exclude (1) exonic variants and (2) variants categorized as "benign". We defined the

ClinVar variant density as the number of the non-coding and non-benign variants within each

annotation x 1,000 divided by the total length (bp) of each annotation.

Somatic mutation analysis

We used a list of somatic mutation hotspot in Supplementary Table 2-20 of the original

publication[94]. We lifted the genomic coordinates to GRCh38 by using LifOver software. We then

intersected the non-coding somatic mutation hotspots with our cell-type-specific SCENT peaks.

We compared the intersected elements' target genes by SCENT with the "Annotate_Gene"

column from the original publication.

Downsampling experiments

To evaluate the effect of cell numbers on the statistical power in detecting significant SCENT

enhancer-gene linkages, we performed downsampling experiments in fibroblast (the most

abundant cell type in arthritis-tissue dataset, n_{cell} = 9,905). We randomly samples cells (n_{cell} =

500, 1000, 2500, 5000, and 7500). We then applied SCENT to each of the subset groups of

cells and defined significant peak-gene links with FDR < 10%. We counted the number of

significant peak-gene links in each of the subset groups of cells, and annotated peaks based on

the distance to the TSS to the target gene.

References

1.   Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of
SNP-trait associations. *Nucleic Acids Res*. 2014;42(Database issue):D1001-6.
doi:10.1093/nar/gkt1229
2.   Visscher PM, Wray NR, Zhang Q, et al. 10 Years of GWAS Discovery: Biology, Function,
and Translation. *Am J Hum Genet*. 2017;101(1):5-22. doi:10.1016/J.AJHG.2017.06.005
3.   Buniello A, Macarthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published
genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic*
Acids Res. 2019;47(D1):D1005-D1012. doi:10.1093/NAR/GKY1120
4.   Claussnitzer M, Cho JH, Collins R, et al. A brief history of human disease genetics. *Nature*
2020 577:7789. 2020;577(7789):179-189. doi:10.1038/s41586-019-1879-7
5.   Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human
genetics. *Nature Reviews Drug Discovery 2013 12:8*. 2013;12(8):581-594.
doi:10.1038/nrd4051
6.   Shendure J, Findlay GM, Snyder MW. Genomic Medicine–Progress, Pitfalls, and Promise.
Cell. 2019;177(1):45-57. doi:10.1016/J.CELL.2019.02.003

7.   Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal
variants by statistical fine-mapping. *Nature Reviews Genetics 2018 19:8*.
2018;19(8):491-504. doi:10.1038/s41576-018-0016-z

8.   Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common
disease-associated variation in regulatory DNA. *Science (1979)*.
2012;337(6099):1190-1195.
doi:10.1126/SCIENCE.1222794/SUPPL_FILE/MAURANO.SM.PDF

9.   Edwards SL, Beesley J, French JD, Dunning M. Beyond GWASs: illuminating the dark
road from association to function. *Am J Hum Genet*. 2013;93(5):779-797.
doi:10.1016/J.AJHG.2013.10.012

10.   Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine
mapping complex trait variants. *Nat Genet*. 2013;45(2):124-130. doi:10.1038/ng.2504

11.   Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene
promoters. *Nature 2012 489:7414*. 2012;489(7414):109-113. doi:10.1038/nature11279

12.   Smemo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form
long-range functional connections with IRX3. *Nature 2014 507:7492*.
2014;507(7492):371-375. doi:10.1038/nature13138

13.   Won H, de La Torre-Ubieta L, Stein JL, et al. Chromosome conformation elucidates
regulatory relationships in developing human brain. *Nature 2016 538:7626*.
2016;538(7626):523-527. doi:10.1038/nature19847

14.   Strober BJ, Elorbany R, Rhodes K, et al. Dynamic genetic regulation of gene expression
during cellular differentiation. *Science*. 2019;364(6447):1287-1290.
doi:10.1126/SCIENCE.AAW0040

15.   Cuomo ASE, Seaton DD, McCarthy DJ, et al. Single-cell RNA-sequencing of
differentiating iPS cells reveals dynamic genetic effects on gene expression. *Nature
Communications 2020 11:1*. 2020;11(1):1-14. doi:10.1038/s41467-020-14457-z

16.   Zhernakova D v., Deelen P, Vermaat M, et al. Identification of context-dependent
expression quantitative trait loci in whole blood. *Nat Genet*. 2017;49(1):139-145.
doi:10.1038/NG.3737

17.   Nathan A, Asgari S, Ishigaki K, et al. Single-cell eQTL models reveal dynamic T cell state
dependence of disease loci. *Nature 2022 606:7912*. 2022;606(7912):120-128.
doi:10.1038/s41586-022-04713-1

18. Wakefield J. A Bayesian Measure of the Probability of False Discovery in Genetic
Epidemiology Studies. *Am J Hum Genet.* 2007;81(2):208. doi:10.1086/519024

19. Maller JB, McVean G, Byrnes J, et al. Bayesian refinement of association signals for 14
loci in 3 common diseases. *Nat Genet.* 2012;44(12):1294-1301. doi:10.1038/NG.2435

20. Hormozdiari F, Kostem E, Kang EY, Pasaniuc B, Eskin E. Identifying causal variants at
loci with multiple signals of association. *Genetics.* 2014;198(2):497-508.
doi:10.1534/GENETICS.114.167908

21. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP:
efficient variable selection using summary data from genome-wide association studies.
Bioinformatics. 2016;32(10):1493-1501. doi:10.1093/BIOINFORMATICS/BTW018

22. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable
selection in regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat*
Methodol. 2020;82(5):1273-1300. doi:10.1111/RSSB.12388

23. Weissbrod O, Hormozdiari F, Benner C, et al. Functionally informed fine-mapping and
polygenic localization of complex trait heritability. *Nature Genetics 2020 52:12.*
2020;52(12):1355-1363. doi:10.1038/s41588-020-00735-5

24. Wojcik GL, Graff M, Nishimura KK, et al. Genetic analyses of diverse populations
improves discovery for complex traits. *Nature 2019 570:7762.* 2019;570(7762):514-518.
doi:10.1038/s41586-019-1310-4

25. Chen MH, Raffield LM, Mousas A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell
Genetics in 746,667 Individuals from 5 Global Populations. *Cell.*
2020;182(5):1198-1213.e14. doi:10.1016/J.CELL.2020.06.045

26. Ishigaki K, Sakaue S, Terao C, et al. Trans-ancestry genome-wide association study
identifies novel genetic mechanisms in rheumatoid arthritis. *medRxiv.*
2021;12:2021.12.01.21267132. doi:10.1101/2021.12.01.21267132

27. Kichaev G, Pasaniuc B. Leveraging Functional-Annotation Data in Trans-ethnic
Fine-Mapping Studies. *Am J Hum Genet.* 2015;97(2):260-271.
doi:10.1016/J.AJHG.2015.06.007

28. Kanai M, Ulirsch JC, Karjalainen J, et al. Insights from complex trait fine-mapping across
diverse populations. *medRxiv.* Published online September 5,
2021:2021.09.03.21262975. doi:10.1101/2021.09.03.21262975

29. Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to
single-variant resolution. *Nature*. 2017;547(7662):173-178. doi:10.1038/NATURE22969

30. Farh KKH, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal
autoimmune disease variants. *Nature 2014 518:7539*. 2014;518(7539):337-343.
doi:10.1038/nature13835

31. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant
resolution using high-density imputation and islet-specific epigenome maps. *Nature*
Genetics 2018 50:11. 2018;50(11):1505-1513. doi:10.1038/s41588-018-0241-6

32. Kichaev G, Yang WY, Lindstrom S, et al. Integrating functional data to prioritize causal
variants in statistical fine-mapping studies. *PLoS Genet*. 2014;10(10).
doi:10.1371/JOURNAL.PGEN.1004722

33. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis
of 111 reference human epigenomes. *Nature 2015 518:7539*. 2015;518(7539):317-330.
doi:10.1038/nature14248

34. Chen L, Ge B, Casale FP, et al. Genetic Drivers of Epigenetic and Transcriptional
Variation in Human Immune Cells. *Cell*. 2016;167(5):1398-1414.e24.
doi:10.1016/j.cell.2016.10.026

35. Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the
human genome. *Nature*. 2012;489(7414):57-74. doi:10.1038/NATURE11247

36. Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and analysis of chromatin state
dynamics in nine human cell types. *Nature 2011 473:7345*. 2011;473(7345):43-49.
doi:10.1038/nature09906

37. Boix CA, James BT, Park YP, Meuleman W, Kellis M. Regulatory genomic circuitry of
human disease loci by integrative epigenomics. *Nature 2021 590:7845*.
2021;590(7845):300-307. doi:10.1038/s41586-020-03145-z

38. Fulco CP, Nasser J, Jones TR, et al. Activity-by-Contact model of enhancer-promoter
regulation from thousands of CRISPR perturbations. *Nat Genet*. 2019;51(12):1664.
doi:10.1038/S41588-019-0538-0

39. Nasser J, Bergman DT, Fulco CP, et al. Genome-wide enhancer maps link risk variants to
disease genes. *Nature 2021 593:7858*. 2021;593(7858):238-243.
doi:10.1038/s41586-021-03446-x

40.   Gazal S, Weissbrod O, Hormozdiari F, et al. Combining SNP-to-gene linking strategies to
939   identify disease genes and assess disease omnigenicity. *Nat Genet.* 2022;54(6):827-836.
940   doi:10.1038/S41588-022-01087-Y

941   41.   Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–Cas technologies and
942   applications. *Nature Reviews Molecular Cell Biology 2019 20:8.* 2019;20(8):490-507.
943   doi:10.1038/s41580-019-0131-5

944   42.   Anzalone A v., Koblan LW, Liu DR. Genome editing with CRISPR–Cas nucleases, base
945   editors, transposases and prime editors. *Nature Biotechnology 2020 38:7.*
946   2020;38(7):824-844. doi:10.1038/s41587-020-0561-9

947   43.   Baglaenko Y, Macfarlane D, Marson A, Nigrovic PA, Raychaudhuri S. Genome editing to
948   define the function of risk loci and variants in rheumatic disease. *Nature Reviews*
949   *Rheumatology 2021 17:8.* 2021;17(8):462-474. doi:10.1038/s41584-021-00637-8

950   44.   Cao J, Cusanovich DA, Ramani V, et al. Joint profiling of chromatin accessibility and gene
951   expression in thousands of single cells. *Science (1979).* 2018;361(6409):1380-1385.
952   doi:10.1126/SCIENCE.AAU0730/SUPPL_FILE/AAU0730_TABLESS1_S13.XLSX

953   45.   Chen S, Lake BB, Zhang K. High-throughput sequencing of the transcriptome and
954   chromatin accessibility in the same cell. *Nature Biotechnology 2019 37:12.*
955   2019;37(12):1452-1457. doi:10.1038/s41587-019-0290-0

956   46.   Ma S, Zhang B, LaFave LM, et al. Chromatin Potential Identified by Shared Single-Cell
957   Profiling of RNA and Chromatin. *Cell.* 2020;183(4):1103-1116.e20.
958   doi:10.1016/J.CELL.2020.09.056

959   47.   Allaway KC, Gabitto MI, Wapinski O, et al. Genetic and epigenetic coordination of cortical
960   interneuron development. *Nature 2021 597:7878.* 2021;597(7878):693-697.
961   doi:10.1038/s41586-021-03933-1

962   48.   Trevino AE, Müller F, Andersen J, et al. Chromatin and gene-regulatory dynamics of the
963   developing human cerebral cortex at single-cell resolution. *Cell.*
964   2021;184(19):5053-5069.e23. doi:10.1016/J.CELL.2021.07.039

965   49.   Granja JM, Corces MR, Pierce SE, et al. ArchR is a scalable software package for
966   integrative single-cell chromatin accessibility analysis. *Nature Genetics 2021 53:3.*
967   2021;53(3):403-411. doi:10.1038/s41588-021-00790-6

968   50.   Stuart T, Srivastava A, Madad S, Lareau CA, Satija R. Single-cell chromatin state analysis
969   with Signac. *Nature Methods 2021 18:11*. 2021;18(11):1333-1341.
970   doi:10.1038/s41592-021-01282-5

971   51.   Pliner HA, Packer JS, McFaline-Figueroa JL, et al. Cicero Predicts cis-Regulatory DNA
972   Interactions from Single-Cell Chromatin Accessibility Data. *Mol Cell*.
973   2018;71(5):858-871.e8. doi:10.1016/J.MOLCEL.2018.06.044

974   52.   Efron B, Tibshirani RJ. An Introduction to the Bootstrap. *An Introduction to the Bootstrap*.
975   Published online May 14, 1994. doi:10.1201/9780429246593

976   53.   Lähnemann D, Köster J, Szczurek E, et al. Eleven grand challenges in single-cell data
977   science. *Genome Biology 2020 21:1*. 2020;21(1):1-35. doi:10.1186/S13059-020-1926-6

978   54.   Sarkar A, Stephens M. Separating measurement and expression models clarifies
979   confusion in single-cell RNA sequencing analysis. *Nature Genetics 2021 53:6*.
980   2021;53(6):770-777. doi:10.1038/s41588-021-00873-4

981   55.   Chen H, Lareau C, Andreani T, et al. Assessment of computational methods for the
982   analysis of single-cell ATAC-seq data. *Genome Biol*. 2019;20(1):1-25.
983   doi:10.1186/S13059-019-1854-5/FIGURES/7

984   56.   Granja JM, Klemm S, McGinnis LM, et al. Single-cell multiomic analysis identifies
985   regulatory programs in mixed-phenotype acute leukemia. *Nature Biotechnology 2019
986   37:12*. 2019;37(12):1458-1465. doi:10.1038/s41587-019-0332-7

987   57.   Luecken MD, Burkhardt DB, Cannoodt R, et al. A sandbox for prediction and integration of
988   DNA, RNA, and proteins in single cells. *Proceedings of the Neural Information Processing
989   Systems Track on Datasets and Benchmarks*. 2021;1. Accessed September 11, 2022.
990   https://openproblems.bio/neurips.

991   58.   Mimitou EP, Lareau CA, Chen KY, et al. Scalable, multimodal profiling of chromatin
992   accessibility, gene expression and protein levels in single cells. *Nat Biotechnol*.
993   2021;39(10):1246-1258. doi:10.1038/S41587-021-00927-2

994   59.   Chen AF, Parks B, Kathiria AS, Ober-Reynolds B, Goronzy JJ, Greenleaf WJ. NEAT-seq:
995   simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene
996   expression in single cells. *Nature Methods 2022 19:5*. 2022;19(5):547-553.
997   doi:10.1038/s41592-022-01461-y

998   60.   Meijer M, Agirre E, Kabbe M, et al. Epigenomic priming of immune genes implicates
999   oligodendroglia in multiple sclerosis susceptibility. *Neuron*. 2022;110(7):1193-1210.e13.
doi:10.1016/J.NEURON.2021.12.034

61.   Zhang Z, Zamojski M, Smith GR, et al. Single nucleus transcriptome and chromatin
accessibility of postmortem human pituitaries reveal diverse stem cell regulatory
mechanisms. *Cell Rep*. 2022;38(10). doi:10.1016/J.CELREP.2022.110467

62.   Abascal F, Acosta R, Addleman NJ, et al. Expanded encyclopaedias of DNA elements in
the human and mouse genomes. *Nature 2020 583:7818*. 2020;583(7818):699-710.
doi:10.1038/s41586-020-2493-4

63.   Westra HJ, Franke L. From genome to function by studying eQTLs. *Biochim Biophys Acta*.
2014;1842(10):1896-1902. doi:10.1016/J.BBADIS.2014.04.024

64.   Hujoel MLA, Gazal S, Hormozdiari F, van de Geijn B, Price AL. Disease Heritability
Enrichment of Regulatory Elements Is Concentrated in Elements with Ancient Sequence
Age and Conserved Function across Species. *Am J Hum Genet*. 2019;104(4):611-624.
doi:10.1016/j.ajhg.2019.02.008

65.   Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate,
insect, worm, and yeast genomes. *Genome Res*. 2005;15(8):1034-1050.
doi:10.1101/GR.3715005

66.   Lek M, Karczewski KJ, Minikel E v., et al. Analysis of protein-coding genetic variation in
60,706 humans. *Nature*. 2016;536(7616):285-291. doi:10.1038/nature19057

67.   Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified
from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443.
doi:10.1038/s41586-020-2308-7

68.   Wang X, Goldstein DB. Enhancer Domains Predict Gene Pathogenicity and Inform Gene
Discovery in Complex Disease. *The American Journal of Human Genetics*.
2020;106(2):215-233. doi:10.1016/J.AJHG.2020.01.012

69.   Aguet F, Barbeira AN, Bonazzola R, et al. The GTEx Consortium atlas of genetic
regulatory effects across human tissues. *Science*. 2020;369(6509):1318.
doi:10.1126/SCIENCE.AAZ1776

70.   Kurki MI, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining
isolated population and national health register data. *medRxiv*. Published online March 6,
2022:2022.03.03.22271360. doi:10.1101/2022.03.03.22271360

71.   Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping
and genomic data. *Nature*. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z
72.   Dey KK, Gazal S, van de Geijn B, et al. SNP-to-gene linking strategies reveal contributions
of enhancer-related and candidate master-regulator genes to autoimmune disease. *Cell*
Genomics. 2022;2:100145. doi:10.1016/j.xgen.2022.100145
73.   Freund MK, Burch KS, Shi H, et al. Phenotype-Specific Enrichment of Mendelian Disorder
Genes near GWAS Regions across 62 Complex Traits. *The American Journal of Human*
Genetics. 2018;103(4):535-552. doi:10.1016/J.AJHG.2018.08.017
74.   Gate RE, Cheng CS, Aiden AP, et al. Genetic determinants of co-accessible chromatin
regions in activated T cells across humans. *Nature Genetics 2018 50:8*.
2018;50(8):1140-1150. doi:10.1038/s41588-018-0156-2
75.   Khetan S, Kursawe R, Youn A, et al. Type 2 Diabetes-Associated Genetic Variants
Regulate Chromatin Accessibility in Human Islets. *Diabetes*. 2018;67(11):2466-2477.
doi:10.2337/DB18-0393
76.   Alasoo K, Rodrigues J, Mukhopadhyay S, et al. Shared genetic effects on chromatin and
gene expression indicate a role for enhancer priming in immune response. *Nat Genet*.
2018;50(3):424. doi:10.1038/S41588-018-0046-7
77.   Currin KW, Erdos MR, Narisu N, et al. Genetic effects on liver chromatin accessibility
identify disease regulatory variants. *Am J Hum Genet*. 2021;108(7):1169-1189.
doi:10.1016/J.AJHG.2021.05.001
78.   Kumasaka N, Knights AJ, Gaffney DJ. Fine-mapping cellular QTLs with RASQUAL and
ATAC-seq. *Nature Genetics 2015 48:2*. 2015;48(2):206-213. doi:10.1038/ng.3467
79.   Chiou J, Geusz RJ, Okino ML, et al. Interpreting type 1 diabetes risk with genetics and
single-cell epigenomics. *Nature 2021 594:7863*. 2021;594(7863):398-402.
doi:10.1038/s41586-021-03552-w
80.   Mouri K, Guo MH, de Boer CG, et al. Prioritization of autoimmune disease-associated
genetic variants that perturb regulatory element activity in T cells. *Nature Genetics 2022*
54:5. 2022;54(5):603-612. doi:10.1038/s41588-022-01056-5
81.   Javierre BM, Sewitz S, Cairns J, et al. Lineage-Specific Genome Architecture Links
Enhancers and Non-coding Disease Variants to Target Gene Promoters. *Cell*.
2016;167(5):1369-1384.e19. doi:10.1016/J.CELL.2016.09.037

82.   Radtke F, Fasnacht N, MacDonald HR. Notch signaling in the immune system. *Immunity*.
1062   2010;32(1):14-27. doi:10.1016/J.IMMUNI.2010.01.004

1063   83.   Wei K, Korsunsky I, Marshall JL, et al. Notch signalling drives synovial fibroblast identity
1064   and arthritis pathology. *Nature*. 2020;582(7811):259-264.
1065   doi:10.1038/S41586-020-2222-Z

1066   84.   Delacher M, Schmidl C, Herzig Y, et al. Rbpj expression in regulatory T cells is critical for
1067   restraining TH2 responses. *Nature Communications 2019 10:1*. 2019;10(1):1-20.
1068   doi:10.1038/s41467-019-09276-w

1069   85.   Blake JA, Baldarelli R, Kadin JA, Richardson JE, Smith CL, Bult CJ. Mouse Genome
1070   Database (MGD): Knowledgebase for mouse–human comparative biology. *Nucleic Acids*
1071   *Res*. 2021;49(D1):D981. doi:10.1093/NAR/GKAA1083

1072   86.   Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome.
1073   *Science (1979)*. 2015;347(6220).
1074   doi:10.1126/SCIENCE.1260419/SUPPL_FILE/1260419_UHLEN.SM.PDF

1075   87.   Hillier SG. Gonadotropic control of ovarian follicular growth and development. *Mol Cell*
1076   *Endocrinol*. 2001;179(1-2):39-46. doi:10.1016/S0303-7207(01)00469-5

1077   88.   Rubinstein WS, Maglott DR, Lee JM, et al. The NIH genetic testing registry: a new,
1078   centralized database of genetic tests to enable access to comprehensive information and
1079   improve transparency. *Nucleic Acids Res*. 2013;41(D1):D925-D935.
1080   doi:10.1093/NAR/GKS1173

1081   89.   Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing
1082   across clinical indications. *Genet Med*. 2016;18(7):696-704. doi:10.1038/GIM.2015.148

1083   90.   Adams DR, Eng CM. Next-Generation Sequencing to Diagnose Suspected Genetic
1084   Disorders. *N Engl J Med*. 2018;379(14):1353-1362. doi:10.1056/NEJMRA1711801

1085   91.   Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary
1086   consensus statement: exome sequencing is a first-tier clinical diagnostic test for
1087   individuals with neurodevelopmental disorders. *Genet Med*. 2019;21(11):2413-2421.
1088   doi:10.1038/S41436-019-0554-6

1089   92.   Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations
1090   and supporting evidence. *Nucleic Acids Res*. 2018;46(D1):D1062-D1067.
1091   doi:10.1093/NAR/GKX1153

1092   93.   Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory Bowel Disease and Mutations
1093   Affecting the Interleukin-10 Receptor. *New England Journal of Medicine*.
1094   2009;361(21):2033-2045.
1095   doi:10.1056/NEJMOA0907206/SUPPL_FILE/NEJM_GLOCKER_2033SA1.PDF
1096   94.   Dietlein F, Wang AB, Fagre C, et al. Genome-wide analysis of somatic noncoding
1097   mutation patterns in cancer. *Science (1979)*. 2022;376(6589).
1098   doi:10.1126/SCIENCE.ABG5601/SUPPL_FILE/SCIENCE.ABG5601_MDAR_REPRODU
1099   CIBILITY_CHECKLIST.PDF
1100   95.   Connally N, Nazeen S, Lee D, et al. The missing link between genetic association and
1101   regulatory function. *medRxiv*. Published online October 13, 2022:2021.06.08.21258515.
1102   doi:10.1101/2021.06.08.21258515
1103   96.   Donlin LT, Rao DA, Wei K, et al. Methods for high-dimensonal analysis of cells dissociated
1104   from cyropreserved synovial tissue. *Arthritis Res Ther*. 2018;20(1):1-15.
1105   doi:10.1186/S13075-018-1631-Y/FIGURES/6
1106   97.   Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. *Cell*.
1107   2019;177(7):1888-1902.e21. doi:10.1016/J.CELL.2019.05.031
1108   98.   Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell
1109   data with Harmony. *Nature Methods 2019 16:12*. 2019;16(12):1289-1296.
1110   doi:10.1038/s41592-019-0619-0
1111   99.   Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of
1112   genomes. *Nat Methods*. 2012;9(2):179-181. doi:10.1038/nmeth.1785
1113   100.   Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and
1114   methods. *Nature Genetics 2016 48:10*. 2016;48(10):1284-1287. doi:10.1038/ng.3656
1115   101.   Gibbs RA, Boerwinkle E, Doddapaneni H, et al. A global reference for human genetic
1116   variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393
1117   102.   van der Auwera G, O'Connor B, Safari an OMCompany. *Genomics in the Cloud.*; 2020.
1118   Accessed December 25, 2021.
1119   https://www.oreilly.com/library/view/genomics-in-the/9781491975183/

1120

1121

Acknowledgments

We would like to sincerely thank participants of this study who provided tissue samples. We

thank Anika Gupta, Joyce Kang and Kaitlyn Lagattuta for their comments and helpful discussion

on the manuscript. This work is supported in part by funding from the National Institutes of

Health (R01AR063759, U01HG012009, UC2AR081023). S.S. was in part supported by the

Uehara Memorial Foundation and The Osamu Hayaishi Memorial Scholarship. K.W. is

supported by a Burroughs Wellcome Fund Career Awards for Medical Scientists, a Doris Duke

Charitable Foundation Clinical Scientist Development Award, and a Rheumatology Research

Foundation Innovative Research Award. We would like to thank the Brigham and Women's

Hospital Center for Cellular Profiling Single Cell Mulitomics Core for experimental design and

protocol optimization.

1133

Author Contributions

1135   S.S. and S.R. conceived the work and wrote the manuscript with critical input from co-authors.

1136   S.S. and K. Weinand analyzed the arthritis-tissue dataset and S.S. analyzed publicly available

1137   datasets with help and guidance from K.K.D., K.J., M.K., A.M., A.L.P., and S.R. G.F.M.W., Z.Z.,

1138   M.B.B., L.T.D., and K.Wei provided samples and generated the arthritis-tissue dataset.

1139

Competing Financial Interests

1141   We declare no conflict of interest for this study. S.R. is a founder for Mestag, Inc, a scientific

1142   advisor for Rheos, Jannsen, and Pfizer, and serves as a consultant for Sanofi and Abbvie.